Doris is 85 and suffers from moisture build up in her eye, what some call wet eye. She is on Medicare and gets treated with Eylea, a Regeneron product, every 4-5 weeks. Each treatment costing $6,200. That is more than $70,000 per year even though Doris never made more than $40,000 while working. Her total out of pocket cost is $10.29 per treatment.
Posts Tagged ‘DRI Capital’
25-Jul 2017: Regeneron’s Eylea: Pulling Open the Curtain on Drug Costs
Posted in bill parish, Drug companies, Uncategorized, tagged 990, Avastin, Bayer, Bloomberg, Cashflow, DRI Capital, Drug companies, Drug costs, Drug Royalty III L.P. 1, Drugmakers, eylea, FDA, Foundations, GoodDays, Health insurance, Healthcare, Income Tax, Insurance, investments, irs, Medicaid, Medicare, OIC, Opthomologists, Oregon-PERS, Pablo Legorreta, Patient Access Network, Patient Cash Flows, public pensions, Regeneron, Royalty, Royalty Pharma, State of Oregon, tax exempt, Tax Inversions, Wet AMD on July 25, 2017|
19-Jul 2017: Is Patient Health Being Mortgaged via Derivatives as Homes Were During the Financial Crisis?
Posted in bill parish, Drug companies, Politics, Uncategorized, World News, tagged 10K, canada, carried interest, Cash flows, Caterpillar, Donald Trump, DRI Capital, Drug companies, Drug Royalty, Drugs, Eli Lilly, Healthcare, Inversions, Investors, Irish, Johnson and Johnson, London stock exchange, management fee, Merck, Mitch McConnell, New York Times, Obamacare, Pablo Legorreta, Patients, Pfizer, Private Equity, Product specific inversion, public pensions, Royalty, Royalty Interests, Royalty Pharma, sec, SEC 10Q, taxes, Trumpcare on July 19, 2017|
Senator McConnell’s Dilemma: To Serve Patients or Investors?
When evaluating health care investments it is important to analyze the structure of leading drug and medical equipment companies. A close look indeed reveals a derivative driven system in which private equity and hedge funds increase demand for drug payments by purchasing the rights to the cash flows from key drugs. Patients are indeed unaware that many of the drugs they consume are now owned in part by private equity investors.
